




FIG. 1




FIG. 3




FIG. 2




FIG. 4




FIG. 5

| Procedure                                                                                                                | Baseline | Treatment Period |       |       |       |       |       |       | Follow-up<br>Day 8 |
|--------------------------------------------------------------------------------------------------------------------------|----------|------------------|-------|-------|-------|-------|-------|-------|--------------------|
|                                                                                                                          |          | Day 1            | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 |                    |
| CER-001 Dosing                                                                                                           |          | X                | X     | X     | X     | X     | X     | X     |                    |
| IL-6                                                                                                                     | X        | X                | X     | X     | X     | X     | X     | X     | X                  |
| Additional Inflammatory Markers <sup>a</sup>                                                                             | X        |                  |       |       |       |       |       |       | X                  |
| Safety Labs <sup>b</sup>                                                                                                 | X        |                  |       |       |       |       |       |       | X                  |
| Concomitant Medication Monitoring                                                                                        | X        | X                | X     | X     | X     | X     | X     | X     | X                  |
| Adverse Event Monitoring                                                                                                 | X        | --->             | --->  | --->  | --->  | --->  | --->  | --->  | X                  |
| <sup>a</sup> Includes CRP, D-dimer, Ferritin, IL-8, GM-CSF, MCP 1 and TNF-α<br><sup>b</sup> Tested at local hospital lab |          |                  |       |       |       |       |       |       |                    |

FIG. 6

| Procedure                                                                                                                                         | Baseline | Treatment Period |       |       |                |       |       |       | Follow-up<br>Day 8 |
|---------------------------------------------------------------------------------------------------------------------------------------------------|----------|------------------|-------|-------|----------------|-------|-------|-------|--------------------|
|                                                                                                                                                   |          | Day 1            | Day 2 | Day 3 | Day 4          | Day 5 | Day 6 | Day 7 |                    |
| CER-001 Dosing                                                                                                                                    |          | X                | X     | X     | X <sup>d</sup> |       |       |       |                    |
| IL-6                                                                                                                                              | X        | X                | X     | X     | X              | X     | X     | X     | X                  |
| Clinical laboratory assessments <sup>a</sup>                                                                                                      | X        | X                | X     | X     | X              | X     | X     | X     | X                  |
| Additional Inflammatory Markers <sup>b</sup>                                                                                                      | X        |                  | X     |       | X              |       | X     |       | X                  |
| Safety Labs <sup>c</sup>                                                                                                                          | X        |                  |       |       |                |       |       |       | X                  |
| Concomitant Medication Monitoring                                                                                                                 | X        | X                | X     | X     | X              | X     | X     | X     | X                  |
| Adverse Event Monitoring                                                                                                                          | X        | --->             | --->  | --->  | --->           | --->  | --->  | --->  | X                  |
| <sup>a</sup> Includes PaO2, PaCO2, P/F Ratio, Modified Borg Dyspnea Scale (MBS), VES, Blood count, LDH, Serum Creatinine, Arterial blood gas test |          |                  |       |       |                |       |       |       |                    |
| <sup>b</sup> Includes CRP, D-dimer, Ferritin, IL-8, GM-CSF, MCP 1 and TNF-α                                                                       |          |                  |       |       |                |       |       |       |                    |
| <sup>c</sup> To be tested at local hospital lab                                                                                                   |          |                  |       |       |                |       |       |       |                    |
| <sup>d</sup> After Day 3, up to two additional doses may be administered at the discretion of the Investigator                                    |          |                  |       |       |                |       |       |       |                    |

FIG. 7




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D




FIG. 8E




FIG. 8F




FIG. 8G






FIG. 8H



**FIG. 8I**



**FIG. 8J**




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D




FIG. 9E




FIG. 9F




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D




FIG. 10E




FIG. 10F




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18A




FIG. 18B




FIG. 18C




FIG. 18D




FIG. 18E




FIG. 18F